PSDV - pSivida Limited Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PSDV - pSivida Limited

PSDV 1.220

+14.0%

Mar 29 5:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: John McCarthy	11/18/2009 5:57:23 PM
	Read Replies (1) of 421

Regeneron gets $20M milestone from Bayer July 24, 2009 — 11:30am ET \| By Maureen Martino Regeneron Pharmaceuticals has enrolled the first patient in a Phase III trial of VEGF Trap-Eye for the treatment of central retinal vein occlusion, triggering a $20 million milestone payment form Bayer Healthcare. The pact was signed in 2006 and gave Regeneron $75 million up front and up to $245 million more in milestone payments for the eye therapy, which treats the leading cause of blindness in adults. The trial results are expected in 2011. Additionally, Regeneron said that it's completed enrollment in a Phase II study of the drug for diabetic macular edema (DME), with the results expected in the first half of 2010. VEGF Trap-Eye is also being investigated for the treatment of the neovascular form of age-related macular degeneration. Regeneron has rights to the drug in the U.S., while Bayer holds ex-U.S. rights. - here's the release Read more: fiercebiotech.com fiercebiotech.com

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next